| LHX |
Report |
Q2 revenue |
BEAT |
pred ~$5.93B vs. cons $5.81B |
MEDIUM |
| LHX |
Report |
Q2 GAAP diluted EPS |
BEAT |
pred ~$2.87 vs. cons $2.80 |
MEDIUM |
| LHX |
Report |
Q2 segment operating margin |
IN-LINE |
pred ~15.9% vs. cons 16.0% |
MEDIUM |
| LHX |
Guide |
Revenue guidance |
BETTER |
guide ~$23.75B midpoint vs. cons $23.58B (FY2026) |
MEDIUM |
| LHX |
Guide |
GAAP diluted EPS guidance |
BETTER |
guide ~$11.60 midpoint vs. cons $11.54 (FY2026) |
MEDIUM |
| LHX |
Guide |
Free cash flow guidance |
UNCHANGED |
guide ~$3.00B vs. cons $2.99B (FY2026) |
HIGH |
| LHX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| LHX |
Return |
5-day cumulative residual |
+1.6% (FADE) |
A revenue and EPS beat plus a modest FY2026 revenue raise should drive the initial gain, but unchanged margin and free-cash-flow guidance imply limited out-period EPS revisions; investment, working-capital and transaction complexity should cause part of the day-1 move to fade. |
MEDIUM |